Delving into the Latest Updates on Yaotang (Nanjing) Biotechnology Co., Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Congenital Disorders

Endocrinology and Metabolic Disease

mRNA

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	1
Nervous System Diseases	1

Top 5 Drug Type	Count

mRNA	1

Top 5 Target	Count

TTR(Transthyretin)	1

主要目的：评价在 ATTR-PN 和 ATTR-CM 患者中给予 YOLT-201 后的安全性和耐受性；次要目的：（1）评价在ATTR-PN和ATTR-CM患者中给予YOLT-201后的药代动力学特征；（2）评价在ATTR-PN和ATTR-CM患者中给予YOLT-201后的药效学特征；（3）评价在ATTR-PN和ATTR-CM患者中给予YOLT-201后的初步有效性；（4）评价在ATTR-PN和ATTR-CM患者中给予YOLT-201后的免疫原性。探索性目的：评价在ATTR-CM患者中给予YOLT-201后的99Tcm-PYP摄取

[Translation]

Primary objectives: To evaluate the safety and tolerability of YOLT-201 in patients with ATTR-PN and ATTR-CM; Secondary objectives: (1) To evaluate the pharmacokinetic characteristics of YOLT-201 in patients with ATTR-PN and ATTR-CM; (2) To evaluate the pharmacodynamic characteristics of YOLT-201 in patients with ATTR-PN and ATTR-CM; (3) To evaluate the preliminary efficacy of YOLT-201 in patients with ATTR-PN and ATTR-CM; (4) To evaluate the immunogenicity of YOLT-201 in patients with ATTR-PN and ATTR-CM. Exploratory objectives: To evaluate the uptake of 99Tcm-PYP in patients with ATTR-CM after YOLT-201 administration

Start Date-

Sponsor / Collaborator

Yaotang (Nanjing) Biotechnology Co., Ltd.

100 Clinical Results associated with Yaotang (Nanjing) Biotechnology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Yaotang (Nanjing) Biotechnology Co., Ltd.

Login to view more data

100 Deals associated with Yaotang (Nanjing) Biotechnology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Yaotang (Nanjing) Biotechnology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 24 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Login to view more data